Biotech Beach
Filter News
Found 72,994 articles
-
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace. -
FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics
5/8/2023
FibroGen, Inc. (Nasdaq: FGEN) and Fortis Therapeutics announced that FibroGen has entered into an exclusive license with Fortis Therapeutics for FOR46, a potential first-in-class Phase 1 antibody-drug conjugate (ADC) targeting a novel epitope on CD46.
-
Trefoil Therapeutics’ Lead Investigational Candidate TTHX1114 Improves Rate of Visual Recovery after Descemet Stripping Only (DSO) in Phase 2 STORM Data Presented at ASCRS Annual Meeting
5/8/2023
Trefoil Therapeutics today announced that TTHX1114 was found to improve the rate of visual recovery and corneal deturgescence (state of relative dehydration maintained by the normal cornea that is necessary for transparency) after Descemet Stripping Only (DSO) in a dose-responsive manner in the Phase 2 STORM study.
-
Singlera Genomics Receives FDA Breakthrough Device Designation for PDACatch, a Liquid Biopsy Assay for Pancreatic Cancer Detection in High-Risk Individuals
5/8/2023
Singlera Genomics today announced that it had received Breakthrough Device Designation from the Food and Drug Administration (FDA) for its PDACatch assay, a novel DNA methylation-based liquid biopsy assay for the detection of pancreatic adenocarcinoma in individuals at high risk for the disease.
-
Illumina Sends Letter to Shareholders Highlighting Board Strength, Weakness of Icahn's Plan
5/8/2023
Illumina (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today issued a shareholder letter highlighting the strength of its Board and noting that Carl Icahn's "plan" for Illumina is sloppy and uninformed.
-
Genome Insight Launches in the U.S. with Innovative Whole Genome Sequencing Approach that Offers Unprecedented, Actionable Insights in Cancer Care
5/8/2023
Genome Insight announced today the U.S. launch of CancerVision, their innovative whole genome sequencing (WGS) test designed to provide accurate, timely and medically meaningful insights that collectively guide personalized healthcare decisions.
-
Edwards' Aortic Valve With Resilia Tissue Shows Favorable Durability, Safety and Efficacy Outcomes in Seven Year Data
5/8/2023
Edwards Lifesciences announced new data from the COMMENCE aortic trial, demonstrating low rates of structural valve deterioration in bioprosthetic aortic valves with the company's innovative RESILIA tissue.
-
Study Validating ClearNote Health’s Avantect Pancreatic Cancer Detection Test Published in the Journal Clinical Gastroenterology and Hepatology
5/8/2023
ClearNote Health™, a cancer detection company focused on enabling people at risk for high-mortality cancers to live longer, healthier lives, today announced the publication of its analytical validation study for the Avantect™ Pancreatic Cancer Test in Clinical Gastroenterology and Hepatology.
-
Kintara Therapeutics to Present at the Sidoti Micro-Cap Virtual Conference
5/8/2023
Kintara Therapeutics, Inc. today announced that its President and CEO, Robert E. Hoffman , will present a corporate overview at the Sidoti Micro-Cap Virtual Conference being held on May 10 – 11, 2023.
-
ImmPACT Bio Announces Opening of California-Based GMP Facility for Clinical Production of IMPT-314, a CD19/CD20 CAR T Therapy for B-Cell Malignancies and Autoimmune Diseases
5/8/2023
ImmPACT Bio USA, Inc. ("ImmPACT Bio"), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer and autoimmune diseases, today announced the opening of the Company's 21,500 square foot Good Manufacturing Practices (GMP) facility in Los Angeles, California.
-
Viracta Therapeutics Reports First Quarter 2023 Financial Results and Provides Clinical Program Updates
5/8/2023
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced financial results for the first quarter of 2023 and recent clinical program updates.
-
Biora Therapeutics to Report First Quarter 2023 Financial Results and Provide Corporate Update
5/8/2023
Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will report first quarter ended March 31, 2023 financial results on Monday, May 15, 2023 after the close of financial markets.
-
Inhibrx Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
5/8/2023
Inhibrx, Inc. (Nasdaq: INBX), or Inhibrx, or the Company, a biopharmaceutical company with four clinical programs in development and a strong emerging pipeline, today reported financial results for the first quarter of 2023 and provided an update on recent corporate highlights.
-
Primmune Therapeutics to Present at the 2023 STING & TLR-Targeting Therapies Summit
5/8/2023
Primmune Therapeutics, a biotech company harnessing the power of the innate immune system to treat solid tumors in the advanced cancer setting and to clear human papillomavirus and related pre-cancerous cervical lesions, today announced that Primmune’s Senior Vice President & Chief Scientific Officer James Appleman, Ph.D., will present at the 4th STING & TLR-Targeting Therapies Summit being held in Boston, Massachusetts from May 9-11, 2023.
-
Xencor Reports First Quarter 2023 Financial Results
5/8/2023
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today reported financial results for the first quarter ended March 31, 2023 and provided a review of recent business and clinical highlights.
-
Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview
5/8/2023
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the first quarter ended March 31, 2023.
-
AbbVie Releases New Data Demonstrating Breadth of Its Gastroenterology Portfolio at 2023 Digestive Disease Week®
5/6/2023
AbbVie announced it will present 29 abstracts during the 2023 Digestive Disease Week Annual Meeting, May 6-9, 2023, being held in Chicago and virtually.
-
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5/5/2023
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on April 24, 2023, the Compensation Committee of Acadia’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 98,850 shares of common stock and 59,934 restricted stock units (“RSUs”) to 44 new employees under Acadia’s 2023 Inducement Plan.
-
Terasaki Institute Holds Grand Opening Celebration at New Research Center
5/5/2023
The Terasaki Institute for Biomedical Innovation, a non-profit research organization devoted to developing bioengineered systems, devices, and technology for biomedical applications, held a Grand Opening celebration at their newest research facility in Woodland Hills.
-
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
5/5/2023
ORIC Pharmaceuticals, Inc. today announced that on May 1, 2023 (the “Grant Date”), ORIC granted a total of 29,800 non-qualified stock options and 4,980 restricted stock units to two new non-executive employees who began their employment with ORIC in April 2023.